Global healthcare products provider Perrigo Company and Elan have entered into a definitive agreement, under which the latter will be acquired by a new holding company in Ireland, New Perrigo, in a $8.6bn cash and stock transaction. ...
Ireland-based biotechnology company Elan has reported a net income of $2.29bn, or $4.28 per share, for the second quarter ended on 30 June 2013 compared to a net loss of $28.5m, or $0.05per share in 2012. Operating loss for the second ...
Biogen Idec and Elan are seeking approvals from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for first-line use of Tysabri (natalizumab) in anti-JCV antibody negative patients with multiple sclerosis (MS). ...
The Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS). The product monograph change will help enable ...
Tags: label change, Health Canada, risk assessment